Orphan Drug Designation for Paxalisib

https://www.kaziatherapeutics.com/site/PDF/9640d28a-0022-4d6…

United States Food
and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia’s
paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highlyaggressive childhood brain cancer.

Up significantly in pre-market trading.

IP

That is really nice to hear!

=sheila